Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clin. 2021;71:209–49.

Google Scholar 

WHO. Breast cancer. https://www.who.int/news-room/fact-sheets/detail/breast-cancer (accessed 15 June 2025).

https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Panorama-des-cancers-en-France-edition-2024 Panorama des cancers en France - édition 2024 - Ref: PANOKFR2024(accessed 28 Nov 2024).

Triple-negative Breast Cancer | Details, Diagnosis, and Signs. https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html (accessed 21 May 2025).

Cancer Statistics. SEER. https://seer.cancer.gov/statistics/index.html (accessed 21 May 2025).

den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161:549–56.

Article  Google Scholar 

Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. npj Breast Cancer. 2022;8:95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skinner KE, Haiderali A, Huang M, Schwartzberg LS. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer. Future Oncol. 2021;17:931–41.

Article  CAS  PubMed  Google Scholar 

O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol. 2021;12:164–82.

Article  PubMed  PubMed Central  Google Scholar 

Kesireddy M, Elsayed L, Shostrom VK, Agarwal P, Asif S, Yellala A, et al. Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers. 2024;16:1791.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15, 1212022).

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.

Article  CAS  PubMed  Google Scholar 

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28.

Article  PubMed  Google Scholar 

Understanding how Estrogen Receptor Positive (ER+) breast cancers evade the immune system - National Breast Cancer Foundation (NBCF) | Donate Online. https://nbcf.org.au/project/understanding-how-estrogen-receptor-positive-er-breast-cancers-evade-the-immune-system/#:~:text=Estrogen%20Receptor%20Positive%20(ER%2B)%20breast%20cancer%20is%20the%20most,of%20all%20breast%20cancer%20cases.https://kusuri.ansm-intra.fr/prodIntra/ (accessed 3 Jun2025).

Statut des récepteurs hormonaux du cancer du sein. https://www-breastcancer-org.translate.goog/pathology-report/hormone-receptor-status?_x_tr_sl=en&_x_tr_tl=fr&_x_tr_hl=fr&_x_tr_pto=rq&_x_tr_hist=true (accessed 6 June 2025).

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49.

Article  CAS  PubMed  Google Scholar 

Surveillance, Epidemiology, and End Results Program. SEER. https://seer.cancer.gov/index.html (accessed 21 May 2025).

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367:1783–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423–33.

Article  CAS  PubMed  Google Scholar 

Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist. 2021;26:827–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. JCO. 2021;39:3938–58.

Article  CAS  Google Scholar 

Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989–29006.

Article  PubMed  PubMed Central  Google Scholar 

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380:741–51.

Article  CAS  PubMed  Google Scholar 

O’Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022;195:127–39.

Article  PubMed  PubMed Central  Google Scholar 

Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. npj Breast Cancer. 2022;8:72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, et al. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. npj Breast Cancer. 2024;10:33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384:1529–41.

Article  CAS  PubMed  Google Scholar 

Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. JCO. 2024;42:1738–44.

Article  CAS  Google Scholar 

Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020;31:1709–18.

Article  CAS  PubMed  Google Scholar 

Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. JCO. 2022;40:3365–76.

Article  CAS  Google Scholar 

Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, et al. TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer. Future Oncol. 2020;16:705–15.

Article  CAS  PubMed  Google Scholar 

De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024;31:572–80.

Article  PubMed  Google Scholar 

Alaklabi S, Roy AM, Zagami P, Chakraborty A, Held N, Elijah J, et al. Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer. JCO Oncol Pr. 2025;21:620–28.

Article  Google Scholar 

Caputo R, Buono G, Piezzo M, Martinelli C, Cianniello D, Rizzo A, et al. Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Front Oncol 14 (2024) https://doi.org/10.3389/fonc.2024.1362641.

Gorantla V, Choski R, Kudrik F, et al. Real-world sacituzumab govitecan treatment patterns and outcomes in second-line or later metastatic triple negative breast cancer: leveraging electronic health records and manual curation of a US database.Presented at: 42nd Annual Miami Breast Cancer Conference. March 6-9, 2025; Miami, Florida. Poster 31. U.S. (2025) https://www.targetedonc.com/view/sacituzumab-govitecan-shows-consistent-efficacy-in-real-world-mtnbc (accessed 2 May 2025).

Reinisch M, Bruzas S, Spoenlein J, Shenoy S, Traut A, Harrach H, et al. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther Adv Med Oncol. 2023;15:175883592312004542023.

Article  Google Scholar 

Hanna D, Merrick S, Ghose A, Devlin MJ, Yang DD, Phillips E, et al. Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer. 2024;130:1916–20.

Article  CAS  PubMed  PubMed Central